论文部分内容阅读
目的探究孟鲁司特钠联合匹多莫德对小儿毛细支气管炎患儿免疫功能的影响。方法选取我院2015年3月~2016年5月收治的60例小儿毛细支气管炎患儿为研究对象,依入院顺序分为对照组和观察组,30例/组。两组患儿均在平喘、抗感染及抗病毒的常规治疗基础上给予孟鲁司特钠,观察组患儿在对照组基础上联合使用匹多莫德。治疗2m后,测定患儿CD4~+、CD8~+及CD4~+/CD8~+水平,观察并记录患儿治疗效果及不良反应发生率。结果两组患儿CD4~+水平及CD4~+/CD8~+水平均较治疗前明显上升,CD8~+水平较治疗前下降,观察组患儿变化程度均优于对照组,差异有统计学意义(P<0.05);观察组治疗有效率高于对照组,差异有统计学意义(P<0.05);对比两组患儿不良反应发生率,差异无统计学意义(P>0.05)。结论孟鲁司特钠联合匹多莫德治疗小儿毛细支气管炎可改善患儿免疫功能,提高治疗有效率,安全性好且效果显著,值得临床推广。
Objective To investigate the effect of montelukast combined with pidotimod on immune function in children with bronchiolitis. Methods A total of 60 children with bronchiolitis admitted to our hospital from March 2015 to May 2016 were selected and divided into control group and observation group according to the sequence of admission, 30 cases / group. Both groups were given montelukast sodium on the basis of conventional treatment of anti-asthma, anti-infective and anti-virus. The children in the observation group were given pidotimod on the basis of the control group. After treatment for 2m, the levels of CD4 ~ +, CD8 ~ + and CD4 ~ + / CD8 ~ + in children were measured. The therapeutic effect and the incidence of adverse reactions in children were observed and recorded. Results The levels of CD4 ~ + and the level of CD4 ~ + / CD8 ~ + in both groups were significantly higher than those before treatment, while the levels of CD8 ~ + in the two groups were significantly lower than those before treatment, and the changes in the observation group were better than those in the control group (P <0.05). The effective rate of treatment in observation group was higher than that in control group, with significant difference (P <0.05). There was no significant difference in the incidence of adverse reactions between two groups (P> 0.05). Conclusion Montelukast combined with pidotimod in the treatment of children with bronchiolitis can improve children’s immune function, improve the treatment efficiency, good safety and significant effect, worthy of clinical promotion.